Amazon is participating in a clinical trial of a vaccine against breast and skin cancer, in collaboration with a cancer research center in Seattle, Washington, according to a regulatory document published on a US government site.

The first notification of this trial, recently noted by the Business Insider site, dates back to last October.

According to the document, the work, which involves only a limited population of 20 people, is due to be completed in November 2023 and will be led by the Fred Hutchinson Cancer Center.

The vaccine uses neo-antigen peptides, molecules that aim to offer a more personalized treatment of cancers.

Asked by AFP for more details, Amazon did not respond immediately.

The group told CNBC that it “(contributed) its scientific and machine learning expertise” as part of this partnership.

“It will be a long, multi-year process,” a spokesperson told CNBC. “If it went further, we would be open to working with other organizations in the field of health and life sciences that may be interested. »

Originally an online book seller, Amazon has continued to diversify since its creation in 1994, from supermarkets (Whole Foods) to streaming (Prime Video), via dematerialized computing (cloud).

In 2020, the Seattle-based giant officially launched prescription drug delivery through its Amazon Pharmacy platform.